Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: Subgroup analysis of the randomised, multicentre FDCC trial

Nephrology Dialysis Transplantation

Volumn 26, Issue 3, 2011, Pages 1073-1079

  Höcker, Britta ^a   Van Gelder, Teun ^b   Martin Govantes, Juan ^c   MacHado, Paula ^d   Tedesco, Helio ^d   Rubik, Jacek ^e   Dehennault, Maud ^f   Garcia Meseguer, Carmen ^g   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^e CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g H La Paz   (Spain)

Author keywords

controlled trial (RCT); efficacy; mycophenolate mofetil; randomised; renal transplantation; safety

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ANEMIA; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; CHILD; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROGNOSIS; RISK FACTORS; SAFETY; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79952177805     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq450     Document Type: Article

References (18)

1. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000;47:215-245 (Pubitemid 30394540)
2. North American Pediatric Renal Trials and Collaborative Studies 2008 Annual Report. http://www.NAPRTCS.org (January 2010, date last accessed)
3. Halloran P, Mathew T, Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomised, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47 (Pubitemid 27036687)
4. Bunchman T, Navarro M, Broyer M et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 2001;16:978-984 (Pubitemid 34026706)
5. Jungraithmayr T, Staskewitz A, Kirste G et al. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 2003;75:454-461 (Pubitemid 36241138)
6. Hocker B, Weber LT, Bunchman T et al. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial. Pediatr Transplant 2005;9:504-511 (Pubitemid 41153272)
7. Jungraithmayr TC, Wiesmayr S, Staskewitz A et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007;83:900-905 (Pubitemid 46682730)
8. European Mycophenolate Mofetil Cooperative Study Group. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-1325
9. Roberti I, Reisman L. A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients. Pediatr Transplant 1999;3:231-235 (Pubitemid 29399945)
10. van Gelder T, Silva HT, de Fijter JW et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008;86:1043-1051
11. Pawinski T, Hale M, Korecka M et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002;48:1497-1504 (Pubitemid 34925784)
12. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000;22:169-173 (Pubitemid 30196820)
13. Weber LT, Hoecker B, Armstrong VW et al. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006;28:623-631 (Pubitemid 44564060)
14. Myara I, Lahiani F, Cosson C et al. Estimated creatinine clearance by the formula of Gault and Cockcroft in renal transplantation. Nephron 1989;51:426-427
15. Schwartz GJ, Muñoz A, Schneider MF et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009;20:629-637
16. van Gelder T, Klupp J, Barten MJ et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001;23:119-128 (Pubitemid 32240138)
17. Kobayashi M, Saitoh H, Tadano K et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004;309:1029-1035 (Pubitemid 38669688)
18. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-2575 (Pubitemid 350294223)